Anthem Biosciences Ltd is Rated Hold
NiveshIQ
NSE: ANTHEM · Healthcare
Anthem Biosciences Ltd.
₹790.00▲ ₹6.10 (+0.78%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ANTHEM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Anthem Biosciences Ltd.
Anthem Biosciences Limited operates as a technology-focused contract research, development, and manufacturing organization, providing end-to-end services across the new chemical entity and new biological entity lifecycles. The company's core business is divided into two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. CRDMO services include target identification, preclinical development, and manufacturing development batches of molecules used for clinical Phase I, II, and III trials. The company also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2. Despite a 7% decline in Q1 revenue due to deferred deliveries, the company remains
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,419 Cr +34.30% | ₹1,845 Cr +30.00% | ₹2,124 Cr +15.20% |
| EBITDA Margin | 40.05% | 41.00% | 46.58% |
| Net Profit | ₹367.31 Cr -4.60% | ₹451.26 Cr +22.90% | ₹616.18 Cr +36.50% |
| EPS | ₹6.54 | ₹8.04 | ₹7.17 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Anthem Biosciences Q1 Revenue ₹418 Cr; EBITDA Margin Strong At 39.6%
Anthem Biosciences Q1: ₹418 கோடி வருவாய்! லாப வரம்பு வலுவாக உள்ளது!
🔒
+ 3 more stories about Anthem Biosciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹418 Cr, PAT ₹120 Cr, EPS ₹2.13, EBITDA margin 42.0%. Growth context: revenue QoQ -31.5%, PAT QoQ -36.5%.
Management commentary points to product launches, approvals, and therapy-mix improvement as the primary near-term growth...
FY26 (last completed FY): revenue ₹2, 124 Cr, PAT ₹616 Cr, EBITDA margin 46.6%, EPS ₹7.17. Year-on-year: revenue YoY +15...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ANTHEM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ANTHEM alongside your other holdings
Unlock full ANTHEM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Anthem Biosciences Ltd.?
NiveshIQ detects active intelligence signals for Anthem Biosciences Ltd. (ANTHEM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Anthem Biosciences Ltd.?
Anthem Biosciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹4,406,083.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.